Acadian Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $74.4M | Buy |
441,371
+90,661
| +26% | +$13.5M | 0.09% | 198 |
|
|
2026
Q1 | $46.2M | Buy |
350,710
+101,556
| +41% | +$13.5M | 0.07% | 244 |
|
|
2025
Q4 | $35.3M | Buy |
249,154
+209,684
| +531% | +$30.4M | 0.06% | 254 |
|
|
2025
Q3 | $5.53M | Buy |
39,470
+36,242
| +1,123% | +$4.91M | 0.01% | 623 |
|
|
2025
Q2 | $404K | Buy |
3,228
+174
| +6% | +$20K | ﹤0.01% | 1182 |
|
|
2025
Q1 | $337K | Buy |
3,054
+383
| +14% | +$48.5K | ﹤0.01% | 1157 |
|
|
2024
Q4 | $364K | Sell |
2,671
-16,321
| -86% | -$2.02M | ﹤0.01% | 1147 |
|
|
2024
Q3 | $2.18M | Buy |
18,992
+14,828
| +356% | +$2.03M | 0.01% | 721 |
|
|
2024
Q2 | $571K | Buy |
4,164
+698
| +20% | +$95.7K | ﹤0.01% | 1155 |
|
|
2024
Q1 | $478K | Sell |
3,466
-27,778
| -89% | -$3.79M | ﹤0.01% | 1018 |
|
|
2023
Q4 | $4.11M | Sell |
31,244
-15,528
| -33% | -$1.79M | 0.02% | 504 |
|
|
2023
Q3 | $5.26M | Buy |
46,772
+22,741
| +95% | +$2.39M | 0.02% | 426 |
|
|
2023
Q2 | $2.26M | Sell |
24,031
-83,629
| -78% | -$8.17M | 0.01% | 666 |
|
|
2023
Q1 | $10.9M | Buy |
107,660
+54,311
| +102% | +$5.65M | 0.05% | 300 |
|
|
2022
Q4 | $6.36M | Buy |
53,349
+20,253
| +61% | +$2.37M | 0.03% | 385 |
|
|
2022
Q3 | $3.51M | Buy |
+33,096
| New | +$3.36M | 0.02% | 498 |
|
|
2022
Q2 | – | Sell |
-293
| Closed | -$27K | – | 1801 |
|
|
2022
Q1 | $27K | Buy |
+293
| New | +$24.8K | ﹤0.01% | 1534 |
|
|
2021
Q3 | – | Sell |
-1,547
| Closed | -$151K | – | 1913 |
|
|
2021
Q2 | $151K | Sell |
1,547
-3,051
| -66% | -$292K | ﹤0.01% | 1520 |
|
|
2021
Q1 | $447K | Buy |
4,598
+3,618
| +369% | +$379K | ﹤0.01% | 1240 |
|
|
2020
Q4 | $94K | Sell |
980
-10,240
| -91% | -$989K | ﹤0.01% | 1770 |
|
|
2020
Q3 | $1.08M | Buy |
11,220
+3,305
| +42% | +$382K | ﹤0.01% | 880 |
|
|
2020
Q2 | $964K | Buy |
7,915
+6,787
| +602% | +$750K | ﹤0.01% | 976 |
|
|
2020
Q1 | $98K | Buy |
1,128
+683
| +153% | +$66.8K | ﹤0.01% | 1353 |
|
|
2019
Q4 | $48K | Buy |
+445
| New | +$46.6K | ﹤0.01% | 1605 |
|
|
2019
Q2 | – | Sell |
-91
| Closed | -$8K | – | 1966 |
|
|
2019
Q1 | $8K | Sell |
91
-370
| -80% | -$30.9K | ﹤0.01% | 1875 |
|
|
2018
Q4 | $32K | Buy |
+461
| New | +$44.2K | ﹤0.01% | 1491 |
|
|
2018
Q1 | – | Sell |
-99
| Closed | -$8K | – | 1779 |
|
|
2017
Q4 | $8K | Buy |
+99
| New | +$6.75K | ﹤0.01% | 1443 |
|
|
2015
Q3 | – | Sell |
-177
| Closed | -$8K | – | 1386 |
|
|
2015
Q2 | $8K | Buy |
+177
| New | +$7.5K | ﹤0.01% | 1212 |
|
Other funds holding NBIX
VPM
VCM
Acadian Asset Management's NBIX Position: Q2 2026 in Review
Acadian Asset Management increased its Neurocrine Biosciences (NBIX) stake by 26% in Q2 2026, buying an estimated $13.5M and bringing the position to 441,371 shares worth $74.4M. The position accounts for 0.09% of the portfolio, ranked #198.
Acadian Asset Management first reported a position in NBIX in Q2 2015 and has held it in 28 quarters since. 642 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Acadian Asset Management held 441,371 shares of Neurocrine Biosciences worth $74.4M as of Q2 2026.
- Acadian Asset Management bought 90,661 Neurocrine Biosciences shares in Q2 2026, an estimated $13.5M.
- Neurocrine Biosciences made up 0.09% of Acadian Asset Management's portfolio in Q2 2026, its #198 holding.
- Acadian Asset Management first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 28 quarters since.
- 642 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.